{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:58:14Z","timestamp":1779184694054,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["SPORE P50 CA58236"],"award-info":[{"award-number":["SPORE P50 CA58236"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30 CA006973-52"],"award-info":[{"award-number":["5P30 CA006973-52"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00262-021-03050-y","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T13:16:09Z","timestamp":1631884569000},"page":"943-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-7596","authenticated-orcid":false,"given":"Harsimar B.","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago","family":"Vidotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna A.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela C.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"3050_CR1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"3050_CR2","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"W Abida","year":"2020","unstructured":"Abida W, Campbell D, Patnaik A et al (2020) Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res 26:2487\u20132496. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0394","journal-title":"Clin Cancer Res"},{"key":"3050_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.2019.37.7_suppl.202","volume":"37","author":"MR Smith","year":"2019","unstructured":"Smith MR, Sandhu SK, Kelly WK et al (2019) Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. J Clin Oncol. 37:202\u2013202. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.202","journal-title":"J Clin Oncol."},{"key":"3050_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.2020.38.6_suppl.119","volume":"38","author":"JS De Bono","year":"2020","unstructured":"De Bono JS, Mehra N, Higano CS et al (2020) TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)\u2014First interim analysis (IA). J Clin Oncol. 38:119\u2013119. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.119","journal-title":"J Clin Oncol."},{"key":"3050_CR5","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D et al (2020) Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38:3763\u20133772. https:\/\/doi.org\/10.1200\/JCO.20.01035","journal-title":"J Clin Oncol"},{"key":"3050_CR6","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"3050_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","volume":"21","author":"V Lee","year":"2016","unstructured":"Lee V, Murphy A, Le DT, Diaz LA Jr (2016) Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 21:1200\u20131211. https:\/\/doi.org\/10.1634\/theoncologist.2016-0046","journal-title":"Oncologist"},{"key":"3050_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"key":"3050_CR9","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1002\/onco.13601","volume":"26","author":"LA Sena","year":"2021","unstructured":"Sena LA, Fountain J, Isaacsson Velho P et al (2021) Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Oncologist 26:e270\u2013e278. https:\/\/doi.org\/10.1002\/onco.13601","journal-title":"Oncologist"},{"key":"3050_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065","journal-title":"Cell"},{"key":"3050_CR11","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1158\/1078-0432.CCR-14-0257","volume":"20","author":"KL Yap","year":"2014","unstructured":"Yap KL, Kiyotani K, Tamura K et al (2014) Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res 20:6605\u20136617. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0257","journal-title":"Clin Cancer Res"},{"key":"3050_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo MY, Seier K, Ostrovnaya I et al (2018) Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 36:1685\u20131694. https:\/\/doi.org\/10.1200\/JCO.2017.75.7740","journal-title":"J Clin Oncol"},{"key":"3050_CR13","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, Howitt BE, Shukla SA et al (2016) Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget 7:13587\u201313598. https:\/\/doi.org\/10.18632\/oncotarget.7277","journal-title":"Oncotarget"},{"key":"3050_CR14","doi-asserted-by":"publisher","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes EE, Walker SM, Taggart LE et al (2017) Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 109:djw199. https:\/\/doi.org\/10.1093\/jnci\/djw199","journal-title":"J Natl Cancer Inst"},{"key":"3050_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal4922","author":"E Nolan","year":"2017","unstructured":"Nolan E, Savas P, Policheni AN et al (2017) Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aal4922","journal-title":"Sci Transl Med"},{"key":"3050_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215381","volume":"14","author":"WX Wen","year":"2019","unstructured":"Wen WX, Leong CO (2019) Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS ONE 14:e0215381. https:\/\/doi.org\/10.1371\/journal.pone.0215381","journal-title":"PLoS ONE"},{"key":"3050_CR17","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","volume":"23","author":"LB Guedes","year":"2017","unstructured":"Guedes LB, Antonarakis ES, Schweizer MT et al (2017) MSH2 loss in primary prostate cancer. Clin Cancer Res 23:6863\u20136874. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0955","journal-title":"Clin Cancer Res"},{"key":"3050_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10689-014-9744-1","volume":"13","author":"C Rosty","year":"2014","unstructured":"Rosty C, Walsh MD, Lindor NM et al (2014) High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Fam Cancer 13:573\u2013582. https:\/\/doi.org\/10.1007\/s10689-014-9744-1","journal-title":"Fam Cancer"},{"key":"3050_CR19","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1172\/JCI121924","volume":"128","author":"D Nava Rodrigues","year":"2018","unstructured":"Nava Rodrigues D, Rescigno P, Liu D et al (2018) Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 128:4441\u20134453. https:\/\/doi.org\/10.1172\/JCI121924","journal-title":"J Clin Invest"},{"issue":"1770\u201382","key":"3050_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu YM, Cieslik M, Lonigro RJ et al (2018) Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173(1770\u201382):e14. https:\/\/doi.org\/10.1016\/j.cell.2018.04.034","journal-title":"Cell"},{"issue":"758\u201369","key":"3050_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG et al (2018) Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174(758\u201369):e9. https:\/\/doi.org\/10.1016\/j.cell.2018.06.039","journal-title":"Cell"},{"key":"3050_CR22","doi-asserted-by":"publisher","first-page":"28561","DOI":"10.18632\/oncotarget.25564","volume":"9","author":"K Boudadi","year":"2018","unstructured":"Boudadi K, Suzman DL, Anagnostou V et al (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561\u201328571. https:\/\/doi.org\/10.18632\/oncotarget.25564","journal-title":"Oncotarget"},{"issue":"489\u201399","key":"3050_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V et al (2020) Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell 38(489\u201399):e3. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.007","journal-title":"Cancer Cell"},{"key":"3050_CR24","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00262-019-02393-x","volume":"68","author":"M Jenzer","year":"2019","unstructured":"Jenzer M, Kess P, Nientiedt C et al (2019) The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunol Immunother 68:1621\u20131633. https:\/\/doi.org\/10.1007\/s00262-019-02393-x","journal-title":"Cancer Immunol Immunother"},{"key":"3050_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00731-4","author":"TL Lotan","year":"2021","unstructured":"Lotan TL, Kaur HB, Salles DC et al (2021) Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol. https:\/\/doi.org\/10.1038\/s41379-020-00731-4","journal-title":"Mod Pathol"},{"key":"3050_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na R, Zheng SL, Han M et al (2017) Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71:740\u2013747. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.033","journal-title":"Eur Urol"},{"key":"3050_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00081","author":"PI Velho","year":"2019","unstructured":"Velho PI, Lim D, Wang H et al (2019) Molecular characterization and clinical outcomes of primary gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.19.00081","journal-title":"JCO Precis Oncol"},{"key":"3050_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","volume":"76","author":"CH Marshall","year":"2019","unstructured":"Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES (2019) Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur Urol 76:452\u2013458. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.002","journal-title":"Eur Urol"},{"key":"3050_CR29","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","volume":"26","author":"H Kaur","year":"2020","unstructured":"Kaur H, Salles DC, Murali S et al (2020) Genomic and clinicopathologic characterization of ATM-deficient prostate cancer. Clin Cancer Res 26:4869\u20134881. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0764","journal-title":"Clin Cancer Res"},{"key":"3050_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research N","year":"2015","unstructured":"Cancer Genome Atlas Research N (2015) The molecular taxonomy of primary prostate cancer. Cell 163:1011\u20131025. https:\/\/doi.org\/10.1016\/j.cell.2015.10.025","journal-title":"Cell"},{"key":"3050_CR31","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"3050_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41379-018-0083-x","volume":"31","author":"HB Kaur","year":"2018","unstructured":"Kaur HB, Guedes LB, Lu J et al (2018) Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 31:1539\u20131552. https:\/\/doi.org\/10.1038\/s41379-018-0083-x","journal-title":"Mod Pathol"},{"key":"3050_CR33","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41416-018-0268-6","volume":"119","author":"JN Patel","year":"2018","unstructured":"Patel JN, Braicu I, Timms KM et al (2018) Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. Br J Cancer 119:1060\u20131066. https:\/\/doi.org\/10.1038\/s41416-018-0268-6","journal-title":"Br J Cancer"},{"key":"3050_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms KM, Abkevich V, Hughes E et al (2014) Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16:475. https:\/\/doi.org\/10.1186\/s13058-014-0475-x","journal-title":"Breast Cancer Res"},{"key":"3050_CR35","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1038\/s41467-018-05570-1","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Furness A, Joshi K et al (2018) Pan-cancer deconvolution of tumour composition using DNA methylation. Nat Commun 9:3220. https:\/\/doi.org\/10.1038\/s41467-018-05570-1","journal-title":"Nat Commun"},{"key":"3050_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2019.02.006","volume":"87","author":"HB Kaur","year":"2019","unstructured":"Kaur HB, Lu J, Guedes LB et al (2019) TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Hum Pathol 87:95\u2013102. https:\/\/doi.org\/10.1016\/j.humpath.2019.02.006","journal-title":"Hum Pathol"},{"key":"3050_CR37","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J et al (2016) Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22:3764\u20133773. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2477","journal-title":"Clin Cancer Res"},{"key":"3050_CR38","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","volume":"23","author":"S Lheureux","year":"2017","unstructured":"Lheureux S, Lai Z, Dougherty BA et al (2017) Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization. Clin Cancer Res 23:4086\u20134094. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2615","journal-title":"Clin Cancer Res"},{"key":"3050_CR39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s41467-021-21245-w","volume":"12","author":"AB Weiner","year":"2021","unstructured":"Weiner AB, Vidotto T, Liu Y et al (2021) Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun 12:935. https:\/\/doi.org\/10.1038\/s41467-021-21245-w","journal-title":"Nat Commun"},{"key":"3050_CR40","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377:2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"key":"3050_CR41","doi-asserted-by":"publisher","first-page":"6533","DOI":"10.1126\/science.abc8697","volume":"371","author":"EH Hsiue","year":"2021","unstructured":"Hsiue EH, Wright KM, Douglass J et al (2021) Targeting a neoantigen derived from a common TP53 mutation. Science 371:6533. https:\/\/doi.org\/10.1126\/science.abc8697","journal-title":"Science"},{"key":"3050_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","volume":"75","author":"ES Antonarakis","year":"2019","unstructured":"Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL (2019) Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol 75:378\u2013382. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.009","journal-title":"Eur Urol"},{"key":"3050_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5801","author":"W Abida","year":"2018","unstructured":"Abida W, Cheng ML, Armenia J et al (2018) Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5801","journal-title":"JAMA Oncol"},{"key":"3050_CR44","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215\u20131228. https:\/\/doi.org\/10.1016\/j.cell.2015.05.001","journal-title":"Cell"},{"key":"3050_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1603144","journal-title":"N Engl J Med"},{"key":"3050_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38:395\u2013405. https:\/\/doi.org\/10.1200\/JCO.19.01638","journal-title":"J Clin Oncol"},{"key":"3050_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMcibr1808772","volume":"379","author":"ES Antonarakis","year":"2018","unstructured":"Antonarakis ES (2018) Cyclin-dependent kinase 12, immunity, and prostate cancer. N Engl J Med 379:1087\u20131089. https:\/\/doi.org\/10.1056\/NEJMcibr1808772","journal-title":"N Engl J Med"},{"key":"3050_CR48","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-20-2371","volume":"27","author":"P Rescigno","year":"2021","unstructured":"Rescigno P, Gurel B, Pereira R et al (2021) Characterizing CDK12-mutated prostate cancers. Clin Cancer Res 27:566\u2013574. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2371","journal-title":"Clin Cancer Res"},{"key":"3050_CR49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/po.19.00399","volume":"4","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Isaacsson Velho P, Fu W et al (2020) CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol 4:370\u2013381. https:\/\/doi.org\/10.1200\/po.19.00399","journal-title":"JCO Precis Oncol"},{"key":"3050_CR50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/po.19.00383","volume":"4","author":"MT Schweizer","year":"2020","unstructured":"Schweizer MT, Ha G, Gulati R et al (2020) CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade. JCO Precis Oncol 4:382\u2013392. https:\/\/doi.org\/10.1200\/po.19.00383","journal-title":"JCO Precis Oncol"},{"key":"3050_CR51","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","volume":"188","author":"MC Haffner","year":"2018","unstructured":"Haffner MC, Guner G, Taheri D et al (2018) Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol 188:1478\u20131485. https:\/\/doi.org\/10.1016\/j.ajpath.2018.02.014","journal-title":"Am J Pathol"},{"key":"3050_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","author":"T Davoli","year":"2017","unstructured":"Davoli T, Uno H, Wooten EC, Elledge SJ (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. https:\/\/doi.org\/10.1126\/science.aaf8399","journal-title":"Science"},{"key":"3050_CR53","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-18-0468","volume":"25","author":"AA Kraya","year":"2019","unstructured":"Kraya AA, Maxwell KN, Wubbenhorst B et al (2019) Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer. Clin Cancer Res 25:4363\u20134374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0468","journal-title":"Clin Cancer Res"},{"key":"3050_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","volume":"147","author":"R Lozano","year":"2021","unstructured":"Lozano R, Salles DC, Sandhu S et al (2021) Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur J Cancer 147:74\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.027","journal-title":"Eur J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03050-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03050-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03050-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T17:25:38Z","timestamp":1647278738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03050-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3050"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03050-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"20 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TLL has received research support from Roche, DeepBio, and Myriad Biosciences. ESA has served as a paid consultant\/advisor for Janssen, Pfizer, Sanofi, Merck, Bristol-Myers Squibb, AstraZeneca, Clovis, Eli Lilly, and Amgen; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Genentech, Novartis, Merck, Bristol-Myers Squibb, AstraZeneca and Constellation; and is a co-inventor of a biomarker technology that has been licensed to Qiagen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Study was conducted with Johns Hopkins Institutional Review Board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Study was conducted under a waiver of consent on de-identified retrospectively collected cases.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Study was conducted under a waiver of consent on de-identified retrospectively collected cases.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}